Ascletis has submitted marketing applications in many European countries as one of the components of Pfizer’s new crown oral drug jqknews

Summary

[Ascletis has submitted marketing applications in many European countries as one of the components of Pfizer’s new crown oral drug]On February 14, Ascletis Pharma issued an announcement announcing that the company has submitted applications to Germany, France, Ireland, and the United Kingdom through European agents. Marketing authorization application for ritonavir (100 mg film-coated tablets). At the same time, ritonavir marketing authorization applications in other regions including European countries, North American countries and Asia-Pacific countries are also expected to be submitted in the near future.

On February 14, Ascletis Pharma releasedannouncementAnnounced that the company has submitted marketing authorization applications for ritonavir (100 mg film-coated tablets) to Germany, France, Ireland and the United Kingdom through European agents. At the same time, ritonavir marketing authorization applications in other regions including European countries, North American countries and Asia-Pacific countries are also expected to be submitted in the near future.

Oral ritonavir tablet is a pharmacokinetic enhancer of various oral antiviral drugs against viral proteases.PfizerOne of the components of the oral antiviral drug Paxlovid (Nematavir tablet + Ritonavir tablet combination package). According to the news released by the State Food and Drug Administration on February 12,PfizerThe import registration of the company’s new coronavirus treatment drug nematevir tablet/ritonavir tablet combination package (ie Paxlovid) has been approved with conditions.

Ascletis ritonavir oral tablet (100 mg) was approved by the State Drug Administration in September 2021. Ascletis Pharma stated that the company continues to negotiate cooperation with domestic and international companies on the commercial supply of ritonavir in China and around the world. At present, the annual production capacity of Ascletis Pharma’s ritonavir oral tablets has been expanded to 100 million tablets, and the expansion can be further accelerated in the future according to market demand.

(Article source: Beijing News)

Article source: Beijing News

Responsible editor: 43

Original title: Ascletis has submitted marketing applications in many European countries as one of the components of Pfizer’s new crown oral drug